Key points are not available for this paper at this time.
BACKGROUND AND PURPOSE: (atsm) to inhibit ferroptosis. EXPERIMENTAL APPROACH: (atsm) was compared to the known antiferroptotic compound liproxstatin-1. KEY RESULTS: -induced lipid peroxidation, consistent with these compounds quenching lipid radicals. CONCLUSIONS AND IMPLICATIONS: (atsm) possesses favourable properties such as oral bioavailability and entry into the brain that make it an attractive investigational product for clinical trials of ferroptosis-related diseases.
Southon et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: